Business Wire

Amazon and National Safety Council Create First-of-its-Kind Partnership to Solve the Most Common Workplace Injury in the U.S.

Share

Today Amazon (NASDAQ:AMZN) and National Safety Council (NSC) announced a five-year partnership to invent new ways to prevent the largest category of workplace injuries in the U.S., musculoskeletal disorders (MSDs). Amazon and NSC have been working together for months on this first-of-its-kind collaboration.

“Through this partnership we’ll be able to solve problems that people face every day so they can live their fullest lives,” said Lorraine Martin, president and CEO of National Safety Council. “Going to work should be a positive, rewarding, and safe experience. We are grateful for the generous support of Amazon to help companies around the world solve this important issue while fueling our nonprofit mission to keep employees safe in the workplace.”

"As a member of Amazon’s onsite safety team, my goal is to do everything I can to keep my fellow employees healthy at work so we all go home safe to our friends and families," said Chelsea Weimer, an hourly employee at Amazon’s fulfillment center in Baltimore, MD. "Amazon has a high standard for safety; this partnership is more proof of that and I can't wait to see the work that's done to help decrease MSDs."

The partnership will aim to prevent MSDs across a variety of industries by engaging key stakeholders, conducting research, inventing new technology and processes, and scaling the results. The collaboration is made possible by Amazon’s $12 million contribution, the largest corporate contribution in the history of NSC, and will include five key components:

Advisory Council: Establishing an international advisory council to bring together safety experts, corporations, and researchers in public and private sectors. The advisory council will work together to review the most promising approaches to MSD prevention, shape the development of partnership components, and engage external parties on MSD prevention.

Pioneering Research: Conducting research utilizing next-generation artificial intelligence, natural language processing, and machine learning tools to explore current and future MSD innovations and trends. The research will be available to all industries to explore and glean insights.

Small Business and University Grants: Providing grants to small businesses, universities, and university students. These grants will fund research and innovation that help companies of all sizes achieve impact.

Innovation Challenge: Incubating and fostering innovative and practical solutions to address MSDs through Innovation Challenge competitions. These competitions will bring together experts to collaborate, iterate, and share techniques and ideas.

Industry Call to Action – The MSD Pledge: Amazon and NSC will share solutions discovered throughout the partnership to inspire change through the creation of The MSD Pledge and a call on other companies to also join the effort to:

  • Track proactive indicators of injuries to ensure proper risk mitigation and implement prevention strategies based on data.
  • Implement an MSD prevention program that includes educating employees and employers about injury prevention.
  • Embrace and drive forward innovative solutions to prevent MSDs and share best practices with other organizations worldwide.

The partnership kicks off in June during National Safety Month and in its first year will focus on launching the advisory council, identifying research partners, analyzing existing data, and developing the grant and Innovation Challenge programs.

“Nothing is more important than the safety of our employees, and this partnership will allow us to dive deep into the best way to reduce MSDs,” said Heather MacDougall, Amazon’s vice president of worldwide workplace health and safety. “National Safety Council has a long history of advancing safe practices in the workplace, and we look forward to working alongside them as well as many other businesses, experts, and students around the world to innovate and solve for this important issue.”

The NSC collaboration is another step in Amazon’s long-term mission to be Earth’s Safest Place to Work, which includes an investment of over $300 million into safety projects in 2021, and a goal to cut its recordable incident rate by 50% by 2025. Every day, Amazon works closely with health and safety experts, conducts thousands of safety inspections inside every building, and actively seeks employee feedback on how to improve their well-being at work.To see inside Amazon’s workplace and learn more about its team and technology, sign up for a fulfillment center tour at www.amazon.com/FCtours.

National Safety Council is America’s leading nonprofit safety advocate—and has been for over 100 years. As a mission-based organization, it works to eliminate the leading causes of preventable death and injury, focusing its efforts on the workplace, roadway, and impairment. It creates a culture of safety to keep people safer not only at work, but also beyond the workplace.

To learn more about employee safety at Amazon, visit www.amazon.com/employee-safety.

To learn more about the partnership, visit www.nsc.org/amazonpartnership.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom